Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The identification of kinase fusions in thyroid carcinomas helps to expand our knowledge about the landscape of oncogenic alterations in PTC.
|
29046324 |
2018 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the best tagging SNPs from our previous PTC study and additionally included SNPs in or near FOXE1 and NKX2-1 genes, known susceptibility loci for thyroid cancer.
|
27207655 |
2016 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twenty-four (27%) of 89 patients were diagnosed with thyroid cancer (50% papillary thyroid carcinoma [PTC], 50% follicular variant of papillary thyroid carcinoma [FVPTC]).
|
25627462 |
2015 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 265 TC, 34 (12.8%) harbored TERT promoter mutations, including 10/153 (6.5%) conventional papillary TC (CPTC), 8/57 (14.0%) follicular variant PTC, 9/30 (30%) tall cell variant PTC, 1/3 (30%) Hurthle cell thyroid cancer (HTC), 1/5 (20%) follicular TC, and 5/13 (38.5%) poorly differentiated TC.
|
26354077 |
2015 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms the occurrence of synchronous MTC and PTC and is the first evidence of the co-existence of melanoma and distinct thyroid cancers of different origin.
|
24858900 |
2014 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR-H was detected in 39.5% of carcinomas (n = 32) from patients with papillary (PTC, 46.2%, n = 18), follicular (29.6%, n = 8), and anaplastic (100.0%, n = 6) but not medullary (0.0%, n = 9) thyroid carcinoma.
|
23746767 |
2013 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.
|
23414134 |
2013 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC is a characteristic genetic alteration frequently found in radiation-induced thyroid cancer in human populations.
|
22136268 |
2011 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though RET/PTC is a specific genetic event in the carcinomas, our results suggested the possibility of RET/PTC as "passenger" abnormalities rather than "driver" oncogenic mutation during thyroid cancer progression, warranting further studies on mechanisms and implication of RET gene instability.
|
19495791 |
2009 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are inversely associated with RAS or RET/PTC oncogenic activation.
|
19878585 |
2009 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
20 years of RET/PTC in thyroid cancer: clinico-pathological correlations.
|
17891236 |
2007 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we use an 18 Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer.
|
16331264 |
2006 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the methylation pattern of 17 gene promoters in nine thyroid cancer cell lines and in 38 primary thyroid carcinomas (13 papillary thyroid carcinoma [PTC], 10 follicular thyroid carcinoma [FTC], 9 undifferentiated thyroid carcinoma [UTC], 6 medullary thyroid carcinoma [MTC]), 12 goiters, and 10 follicular adenomas (FA) by methylation- specific polymerase chain reaction (PCR).
|
16889486 |
2006 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
|
15368067 |
2005 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data identify a relationship between the methylation-associated silencing of the tumor-suppressor gene SLC5A8 and the T1796A point mutation of the BRAF gene in the PTC-cf. subtype of thyroid carcinomas.
|
15687339 |
2005 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of CD82 and CD63 was analysed by reverse transcriptase-PCR (RT-PCR) and immunohistochemistry in benign goiter (n=12) and 75 primary thyroid carcinoma tissue specimens (PTC: 33, FTC: 24, UTC: 18) out of which 36 were non-metastasized primary tumors and 39 were metastasized tumors (regional lymph node and/or distant metastases).
|
15375577 |
2004 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ret/PTC rearrangements were identified in 42.9% of thyroid carcinoma and 46.2% of adenoma subjects.
|
15126554 |
2004 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated that there is a high preponderance of ras and ret/PTC oncogenes in the evolution of thyroid cancer.
|
12240753 |
2002 |